In current, just only the role of Notch1 or N1IC protein in cancer therapies have been reported [42,43], which demonstrated that rescue of notch1 signaling in antigen-specific CD8+ T cells enhances immunotherapy in cancer [42], and γ-secretase (in Notch signaling) inhibitor PF-03084014 and docetaxel (activating Notch pathway) can synergistically effect on therapy of breast cancer [43]. Here, CD8A is linked to cancer.